Pre-Treatment Hemoglobin Concentration and Absolute Monocyte Count as Independent Prognostic Factors for Survival in Localized or Locally Advanced Prostate Cancer Patients Undergoing Radiotherapy
Authors:
- Łukasz MagrowskiŁMŁukasz Magrowski
- Oliwia MasriOMOliwia Masri
- Jakub CiepałJCJakub Ciepał
- Gabriela DepowskaGDGabriela Depowska
- Zuzanna NowickaZNZuzanna Nowicka
- Rafał StandoRSRafał Stando
- Krystyna ChimiakKCKrystyna Chimiak
- Gabriela BylicaGBGabriela Bylica
- Barbara CzaplaBCBarbara Czapla
- Małgorzata MasriMMMałgorzata Masri
- Franciszek CichurFCFranciszek Cichur
- Iwona JabłońskaIJIwona Jabłońska
Open Access
- 8 October 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (10) , 2514
Abstract
The prognostic value of inflammatory indices, such as the absolute monocyte count (AMC), has been a subject of interest in recent prostate cancer (PCa) studies, while hemoglobin concentration (HGB) has been recognized as a survival factor in castration-resistant metastatic prostate cancer, but its value remains unclear in localized diseases. The aim of this study was to test the prognostic value of these two simple and inexpensive biomarkers for survival and was based on a cohort of 1016 patients treated with primary radiotherapy and androgen deprivation therapy for localized or locally advanced intermediate- or high-risk PCa. Complete survival data were available for all cases and were based on the National Cancer Registry, with a median observation time of 120 months (Interquartile Range (IQR) 80.9–144.7). Missing blood test data were supplemented using the Nearest Neighbor Imputation, and the Cox Proportional Hazards Regression model was used for analysis. The median age was 68.8 years (IQR 63.3–73.5). The five-year overall survival was 82.8%, and 508 patients were alive at the time of analysis. The median time between blood tests and the first day of radiotherapy was 6 days (IQR 0–19). HGB (p = 0.009) and AMC (p = 0.003) were independent prognostic factors for survival, along with age, Gleason Grade Group, clinical T stage and maximum prostate-specific antigen concentration. This study demonstrates that HGB and AMC can be useful biomarkers for overall survival in patients treated with radiotherapy for localized intermediate- or high-risk PCa.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Long-Term Functional Outcomes after Treatment for Localized Prostate CancerNew England Journal of Medicine, 2013
- Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancerRadiation Oncology, 2012
- The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphomaLeukemia & Lymphoma, 2012
- Impact of Comorbidity on Survival Among Men With Localized Prostate CancerJournal of Clinical Oncology, 2011
- Hemoglobin Level VariabilityClinical Journal of the American Society of Nephrology, 2008
- The prognostic value of hemoglobin change after initiating androgen‐deprivation therapy for newly diagnosed metastatic prostate cancerCancer, 2006
- Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meetingProstate Cancer and Prostatic Diseases, 2006
- A Prospective Study of Anemia Status, Hemoglobin Concentration, and Mortality in an Elderly CohortArchives of internal medicine (1960), 2005
- Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high‐risk prostate cancerCancer, 2002